Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More
BIOCON | GSK PHARMA | BIOCON / GSK PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 30.6 | -80.8 | - | View Chart |
P/BV | x | 3.9 | 12.0 | 32.2% | View Chart |
Dividend Yield | % | 0.3 | 1.3 | 19.3% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-19 |
GSK PHARMA Mar-19 |
BIOCON / GSK PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 707 | 3,595 | 19.7% | |
Low | Rs | 554 | 1,253 | 44.2% | |
Sales per share (Unadj.) | Rs | 91.9 | 184.7 | 49.8% | |
Earnings per share (Unadj.) | Rs | 16.7 | 26.3 | 63.6% | |
Cash flow per share (Unadj.) | Rs | 24.2 | 29.2 | 82.9% | |
Dividends per share (Unadj.) | Rs | 1.00 | 20.00 | 5.0% | |
Dividend yield (eoy) | % | 0.2 | 0.8 | 19.2% | |
Book value per share (Unadj.) | Rs | 101.6 | 126.3 | 80.5% | |
Shares outstanding (eoy) | m | 600.00 | 169.40 | 354.2% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 6.9 | 13.1 | 52.3% | |
Avg P/E ratio | x | 37.7 | 92.2 | 40.9% | |
P/CF ratio (eoy) | x | 26.1 | 83.1 | 31.4% | |
Price / Book Value ratio | x | 6.2 | 19.2 | 32.3% | |
Dividend payout | % | 6.0 | 76.1 | 7.9% | |
Avg Mkt Cap | Rs m | 378,330 | 410,626 | 92.1% | |
No. of employees | `000 | 6.1 | 5.0 | 123.6% | |
Total wages/salary | Rs m | 11,653 | 5,372 | 216.9% | |
Avg. sales/employee | Rs Th | 8,994.3 | 6,306.7 | 142.6% | |
Avg. wages/employee | Rs Th | 1,900.7 | 1,083.1 | 175.5% | |
Avg. net profit/employee | Rs Th | 1,635.3 | 898.0 | 182.1% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 55,144 | 31,281 | 176.3% | |
Other income | Rs m | 1,444 | 1,023 | 141.1% | |
Total revenues | Rs m | 56,588 | 32,304 | 175.2% | |
Gross profit | Rs m | 15,883 | 6,009 | 264.3% | |
Depreciation | Rs m | 4,478 | 486 | 921.4% | |
Interest | Rs m | 709 | 6 | 11,816.7% | |
Profit before tax | Rs m | 12,140 | 6,540 | 185.6% | |
Minority Interest | Rs m | 9 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 287 | 0.0% | |
Tax | Rs m | 2,123 | 2,373 | 89.5% | |
Profit after tax | Rs m | 10,026 | 4,454 | 225.1% | |
Gross profit margin | % | 28.8 | 19.2 | 149.9% | |
Effective tax rate | % | 17.5 | 36.3 | 48.2% | |
Net profit margin | % | 18.2 | 14.2 | 127.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 48,228 | 20,061 | 240.4% | |
Current liabilities | Rs m | 30,376 | 14,543 | 208.9% | |
Net working cap to sales | % | 32.4 | 17.6 | 183.5% | |
Current ratio | x | 1.6 | 1.4 | 115.1% | |
Inventory Days | Days | 68 | 57 | 120.3% | |
Debtors Days | Days | 86 | 14 | 608.1% | |
Net fixed assets | Rs m | 64,130 | 14,343 | 447.1% | |
Share capital | Rs m | 3,000 | 1,694 | 177.1% | |
"Free" reserves | Rs m | 57,980 | 19,704 | 294.3% | |
Net worth | Rs m | 60,980 | 21,398 | 285.0% | |
Long term debt | Rs m | 15,766 | 2 | 788,300.0% | |
Total assets | Rs m | 121,924 | 39,113 | 311.7% | |
Interest coverage | x | 18.1 | 1,091.0 | 1.7% | |
Debt to equity ratio | x | 0.3 | 0 | 276,619.7% | |
Sales to assets ratio | x | 0.5 | 0.8 | 56.6% | |
Return on assets | % | 8.8 | 11.4 | 77.2% | |
Return on equity | % | 16.4 | 20.8 | 79.0% | |
Return on capital | % | 16.8 | 31.9 | 52.5% | |
Exports to sales | % | 28.1 | 0 | - | |
Imports to sales | % | 18.9 | 0 | - | |
Exports (fob) | Rs m | 15,506 | NA | - | |
Imports (cif) | Rs m | 10,399 | NA | - | |
Fx inflow | Rs m | 15,506 | 534 | 2,903.7% | |
Fx outflow | Rs m | 10,399 | 7,091 | 146.7% | |
Net fx | Rs m | 5,107 | -6,557 | -77.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 11,546 | 3,994 | 289.1% | |
From Investments | Rs m | -7,138 | -1,433 | 498.0% | |
From Financial Activity | Rs m | -2,417 | -3,584 | 67.4% | |
Net Cashflow | Rs m | 2,103 | -1,023 | -205.5% |
Indian Promoters | % | 40.4 | 0.0 | - | |
Foreign collaborators | % | 20.6 | 50.7 | 40.6% | |
Indian inst/Mut Fund | % | 8.4 | 10.2 | 82.4% | |
FIIs | % | 10.7 | 23.8 | 45.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 19.9 | 15.4 | 129.2% | |
Shareholders | 109,995 | 102,036 | 107.8% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON With: DISHMAN PHARMA CADILA HEALTHCARE VENUS REMEDIES DR. DATSONS LABS GLENMARK PHARMA
Compare BIOCON With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Share markets in India are presently trading on a negative note. The BSE Sensex is trading up by 357 points, up 0.7% at 49,267 levels.
BIOCON share price is trading down by 10% and its current market price is Rs 424. The BSE HEALTHCARE is down by 1.2%. The top gainers in the BSE HEALTHCARE Index are AUROBINDO PHARMA (up 1.7%) and FORTIS HEALTHCARE (up 0.9%). The top losers is BIOCON (down 10.1%).
SRF share price is trading down by 5% and its current market price is Rs 5,715. The BSE 500 is up by 0.3%. The top gainers in the BSE 500 Index are JK TYRE & IND (up 14.5%) and CYIENT (up 11.1%). The top losers are SRF (down 5.1%) and BIOCON (down 8.7%).
BIOCON share price is trading down by 6% and its current market price is Rs 424. The BSE HEALTHCARE is down by 0.2%. The top gainers in the BSE HEALTHCARE Index are PROCTER & GAMBLE HEALTH (up 2.6%) and JUBILANT LIFE SCIENCES (up 1.5%). The top losers is BIOCON (down 6.1%).
For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More